INDEPENDENT RESEARCH MONITOR
Methodology
How both research tracks are discovered, checked, reviewed and published — and where coverage remains limited.
Two tracks, one process
MyelinWatch follows emerging MS treatments and myelin-repair or related neurorepair programmes through one discovery, checking and publication process. A programme can belong to both tracks without being duplicated.
How evidence is separated
Results that test possible benefit in people are kept separate from safety-only studies, planned studies, animal experiments and cell research. Changes in scans, electrical nerve tests or laboratory measurements are described as early signs, not as proof that symptoms or disability improved.
What counts as an update
Important updates include a new study registration, the first participant receiving treatment, a change in enrolment, a pause or stop, a safety concern, official permission to proceed, results, and publication in a scientific journal. Repeated publicity without a real change is not treated as news.
Sources and coverage limits
We check official study registries, scientific papers, regulators and official research sources. A registry entry shows that a study is registered; it does not prove benefit. If a source cannot be checked, we do not treat that as evidence that nothing changed.
Human review before publication
Automation can flag a possible development, but it does not publish medical claims on its own. Before a new or materially changed claim appears publicly, its source and wording are reviewed.
Scope and limitations
This is not a complete or real-time map of all MS research, an independent medical-review service, a treatment ranking or personal medical advice. Negative, null, mixed, safety and stopped developments remain visible when they are relevant.